Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 May 2:3:11.
doi: 10.1186/1750-1172-3-11.

Adaptive design methods in clinical trials - a review

Shein-Chung Chow  1 , Mark Chang
Affiliations
Review

Adaptive design methods in clinical trials - a review

Shein-Chung Chow et al. Orphanet J Rare Dis. .

Abstract

In recent years, the use of adaptive design methods in clinical research and development based on accrued data has become very popular due to its flexibility and efficiency. Based on adaptations applied, adaptive designs can be classified into three categories: prospective, concurrent (ad hoc), and retrospective adaptive designs. An adaptive design allows modifications made to trial and/or statistical procedures of ongoing clinical trials. However, it is a concern that the actual patient population after the adaptations could deviate from the originally target patient population and consequently the overall type I error (to erroneously claim efficacy for an infective drug) rate may not be controlled. In addition, major adaptations of trial and/or statistical procedures of on-going trials may result in a totally different trial that is unable to address the scientific/medical questions the trial intends to answer. In this article, several commonly considered adaptive designs in clinical trials are reviewed. Impacts of ad hoc adaptations (protocol amendments), challenges in by design (prospective) adaptations, and obstacles of retrospective adaptations are described. Strategies for the use of adaptive design in clinical development of rare diseases are discussed. Some examples concerning the development of Velcade intended for multiple myeloma and non-Hodgkin's lymphoma are given. Practical issues that are commonly encountered when implementing adaptive design methods in clinical trials are also discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Response-adaptive randomization.
Figure 2
Figure 2
Sample size re-estimation.
Figure 3
Figure 3
Phase II/III seamless trial design.
Figure 4
Figure 4
Non-Hodgkin's lymphoma trial.
See this image and copyright information in PMC

References

    1. Woodcock J. "FDA introduction comments: clinical studies design and evaluation issues". Clinical Trials. 2005;2:273–275. doi: 10.1191/1740774505cn096oa. - DOI - PubMed
    1. Wei LJ. "The adaptive biased-coin design for sequential experiments". Annal of Statistics. 1978;9:92–100. doi: 10.1214/aos/1176344068. - DOI
    1. Efron B. "Forcing a sequential experiment to be balanced". Biometrika. 1971;58:403–417. doi: 10.1093/biomet/58.3.403. - DOI
    1. Lachin JM. "Statistical properties of randomization in clinical trials". Controlled Clinical Trials. 1988;9:289–311. doi: 10.1016/0197-2456(88)90045-1. - DOI - PubMed
    1. Rosenberger WF, Stallard N, Ivanova A, Harper CN, Ricks ML. "Optimal adaptive designs for binary response trials". Biometrics. 2001;57:909–913. doi: 10.1111/j.0006-341X.2001.00909.x. - DOI - PubMed